By BioGroup Team:
By Roy Vimer, BA, and Nir Etkovitz, PhD
KaloBios Pharmaceuticals (KBIO) is a small-cap biopharmaceutical company that focuses on developing patient-targeted, first-in-class monoclonal antibodies. The KBIO's patented Humaneered® antibody technology platform is used to treat serious medical conditions with a primary clinical emphasis on respiratory diseases and cancer. The customized antibodies production strategy by KaleBios' Humaneered® technology converts non-human antibodies, usually from mice, into recombinant antibodies that have a high binding affinity to their target, high manufacturing yields, and minimal to no immunogenicity (inappropriate immune response) when used repeatedly. KaloBios believes that its Humaneered® strategy allows a true alternative to the classic antibody engineering technologies. KalBios novel system offers important economic and clinical advantages over antibodies produced by classic engineering methods which makes KalBios more suitable for chronic treatments.
Product Pipeline
KaloBios has three Humaneered® antibodies being tested in four clinical development programs for respiratory diseases and cancer (See
Complete Story »